Form 8-K - Current report:
SEC Accession No. 0001610618-23-000022
Filing Date
2023-03-23
Accepted
2023-03-23 07:05:11
Documents
14
Period of Report
2023-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cdtx-20230323.htm   iXBRL 8-K 29625
2 EARNINGS RELEASE ex991-2023x03x23.htm EX-99.1 74578
6 GRAPHIC cidaralogoa.jpg GRAPHIC 63449
  Complete submission text file 0001610618-23-000022.txt   333679

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20230323.xsd EX-101.SCH 1897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20230323_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20230323_pre.xml EX-101.PRE 13046
8 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20230323_htm.xml XML 4281
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 23754437
SIC: 2836 Biological Products, (No Diagnostic Substances)